Scientists have developed a new way to produce, isolate, and ship astatine-211 (At-211), a rare and unstable radioactive isotope with strong potential for targeted cancer therapy.
Known as a “Goldilocks isotope,” At-211 is considered ideal for cancer treatment because it delivers powerful, localized bursts of energy that can kill cancer cells without harming nearby healthy tissue. When At-211 decays, it emits alpha particles—tiny, high-energy projectiles that travel only a short distance, making them highly effective for destroying cancer at the cellular level. The isotope also has a short half-life of 7.2 hours, which helps reduce long-term toxicity, and it decays cleanly without producing harmful secondary radiation.
Using its K150 cyclotron and support from the U.S. Department of Energy, the research team created a patent-pending automated system that rapidly separates At-211 from its bismuth target. A new resin-column trapping method allows faster purification and shipping of larger quantities, minimizing decay during transport and expanding access to researchers.
Targeted alpha therapy using At-211 has shown promising results in fighting blood cancers, ovarian tumors, and certain brain cancers, and researchers are also exploring its potential use in Alzheimer’s disease. With these advances, scientists hope to overcome At-211’s limited availability and make this powerful isotope a key tool in the future of nuclear medicine.